☰Menu

Advanced Prostate Cancer Treatment Options

Author: Lund University
Published: 12 Aug 2011 - Updated: 30 May 2024
Publication Details: Peer-Reviewed | Findings

Table of Contents:
Synopsis - Overview - Related Content

Synopsis

Prostate cancer that has become resistant to hormone treatment and does not respond to radiation or chemotherapy requires new methods of treatment.

Overview

By attacking stem cell-like cells in prostate cancer, researchers at Lund University are working on a project to develop a new treatment option.

A successful interdisciplinary project is underway between two research groups, in which senior researcher Rebecka Hellsten and Professor Anders Bjartell at the Faculty of Medicine's division for Urological Cancer Research, Skane University Hospital in Malma, and Professor Olov Sterner and Assistant Professor Martin Johansson at the Lund University division of Organic Chemistry recently published their latest research findings in the scientific online journal PLoS ONE.

"Prostatic tumors are thought to consist only of about 0.1 percent cancer stem cells, but if you are not successful in eradicating that tumor cell population, there is a risk of subsequent uncontrolled growth of the tumor. The cancer stem cells are often unresponsive to both hormonal treatment and to chemotherapy, so it is essential to develop a direct treatment towards all types of cancer cells", says Anders Bjartell.

Exploring the tumor biology of prostate cancer, the research group have now observed that the protein STAT3 is active in the stem cell-like cells. In their previous studies, they have proven that the natural compound galiellalactone affects STAT3 and has inhibitory effects on the growth of prostate cancer.

Through the development of new specific STAT3-inhibitors with galiellalactone as a model, the researchers hope to develop targeted therapies that attack the stem cell-like cancer cells in prostate cancer and prevent the tumor from growing and spreading.

Publication

Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells, published in PLoS ONE.

Attribution/Source(s): This peer-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally issued as a press release by Lund University and published on 12 Aug 2011. Last updated on 30 May 2024. This content may have been edited for style, clarity, or brevity.

Renaming Low-Risk Prostate Cancer May Save Lives Each Year

Relabeling Grade Group 1 prostate cancer as a precancerous condition could curb overtreatment, increase PSA screening and prevent deaths, a UCLA-led model finds. Published: 1 Jul 2026.

Two-Week Radiotherapy Matches Eight-Week Prostate Cancer Treatment

A decade-long phase 3 trial shows 2 week radiotherapy is as safe and effective as 8 week treatment for prostate cancer, with similar survival and side effects. Published: 5 May 2025.

PI-RADS Score Chart: Prostate MRI Cancer Assessment

PI-RADS is a standardized 1 to 5 scoring system that uses prostate mpMRI to assess the likelihood of clinically significant cancer and guide biopsies. Published: 27 Jan 2025.

Gleason Scores and Grade Groups in Prostate Cancer Explained

Learn how Gleason scores and Grade Groups 1 to 5 rate prostate cancer aggressiveness, why 3+4 differs from 4+3, and how the grade guides treatment choices. Published: 26 Jan 2025.

See the full list of publications

Share or cite this page:

<a href="https://www.disabled-world.com/health/cancer/prostate/advanced.php">Advanced Prostate Cancer Treatment Options</a>: Prostate cancer that has become resistant to hormone treatment and does not respond to radiation or chemotherapy requires new methods of treatment.

While we aim to provide accurate, up-to-date information, our content is for general informational purposes only and is not a substitute for professional advice. Consult a qualified professional about your specific situation.

BACK TO TOP